Moderna Shares Surge Following Cancer Treatment Breakthrough

Moderna's stock price jumped 131% after the company reported a successful Phase 3 trial for its cancer treatment, outperforming the current standard of care. The rally resulted in $4.8 billion in losses for short sellers.